is mounjaro a semaglutide or tirzepatide TrimRX Weight loss drugs like Mounjaro

Semaglutide mimics a natural hormone called GLP-1 (glucagon-like peptide-1), which: Slows digestion (gastric emptying) Regulates appetite and cravings Improves insulin sensitivity Lowers blood sugar levels Glycine , while not directly tied to weight loss, supports: Mitochondrial function and metabolic energy production Anti-inflammatory and antioxidant pathways Sleep quality, cognitive function, and tissue repair The addition of glycine may help reduce the systemic stress of rapid weight loss, support recovery, and enhance metabolic flexibility during your transformation

A chronic cough is one that lasts eight weeks or longer.Additionally, these users were also more prone to be diagnosed with gastroesophageal reflux disease (GERD), which can trigger a dry cough.This cohort study suggests that there is an association between GLP-1 receptor agonist use and new diagnosis of chronic cough, wrote the study authors.However, they stressed that more research is needed to establish a definitive link and to better understand the biological mechanisms behind the new potential side effect.Note: The information provided in this article is for educational purposes only and is not intended as medical advice

Chronic kidney disease represents another expansion opportunity, supported by data demonstrating renal protection independent of glycemic effects [2]

2535% loss rates) 11:05 What efficacy estimate really means (race-track analogy) 13:28 Real-world view: treatment-regimen estimate (2023.7%) vs trial ideal 15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ 18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences) 21:02 Why the lower doses matter & who actually needs 30% weight loss 24:15 From just make the scale go down to quality of weight loss & body composition 28:05 Future focus: health, longevity, and peptides beyond hitting goal weight 30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & talk to your doctor 34:38 How retatrutide changes the next decade of obesity treatment conversations 37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook 40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review 45:20 Why small-molecule oral GLP-1s arent the same as injectable peptides 48:40 New topic: Indiana Safe Drug Act of 2025 and why Dave is concerned 51:02 Production caps, essentially a copy language & shifting power from prescribers to FDA 54:28 How the bill undermines personalization while ignoring real safety tools 57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting 59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors 1:02:05 Call to action: petition at otplinks.com & why patient voices matter 1:05:10 Change.org impact, media attention & centering the patient perspective 1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks Visit Our Sponsors

Mechanism: Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors

Key questions to discuss with your provider include: What is my individual cancer risk based on my medical and family history